Search
Cyclizine
go.drugbank.com/drugs/DB01176ApprovedWithdrawnA histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
Categories: Antihistamines for Systemic UseL-Acetylleucine
go.drugbank.com/drugs/DB16956ApprovedInvestigationalDL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]
Sodium sulfate
go.drugbank.com/drugs/DB09472ApprovedInvestigationalVet approvedSodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. … Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion
Mixtures: FORTRANS FOR ORAL SOLUTIONCategories: Drugs for ConstipationDaclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnHCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. … According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseDihydrostreptomycin
go.drugbank.com/drugs/DB11512ApprovedVet approvedWithdrawnThe FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]
Glycyrrhizic acid
go.drugbank.com/drugs/DB13751ApprovedInvestigationalWhen extracted from the plant, it can be obtained in the form of ammonium glycyrrhizin and mono-ammonium glycyrrhizin. … [F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigationalSimilar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins
Mixtures: IMIPENEM /CILASTATIN KABI POWDER FOR SOLUTION FOR INFUSION 500MG/500MG, IMIPENEM /CILASTATIN Kabi 500 mg/ 500 mg, Powder for solution for infusionCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316] … [L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD).
Thymidine
go.drugbank.com/drugs/DB04485ApprovedInvestigationalThymidine is a naturally occurring deoxyribonucleoside that is a crucial component of the DNA salvage pathway and a building block for DNA synthesis. … [A274683] While it lacks significant anti-tumor activity on its own,[A274688] it has been extensively investigated for nearly a decade as a biochemical modulator to enhance the efficacy and reduce the
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249025,L42065] This delivery platform gives vutrisiran high potency and metabolic stability, and allows for subcutaneous injections to take place once every three months. … [L42085] Another siRNA indicated for the treatment of polyneuropathy associated with hereditary ATTR is [patisiran].[A249010] Vutrisiran was approved by the FDA in June 2022.